Alzheimers Disease Research Company Receives $1,000,000 financial commitment which will enable it to Rapidly Advance Corporate Development
Online PR News – 06-November-2015 – Braincure-Biotech.com today announced that the company has executed an agreement with a large venture capital firm to purchase shares in value of 1 million USD. These funds will be used to support financial and business development goals that will help the company accelerate its research and testing programs, currently focused on the development of a new treatment in the fight against Alzheimers Disease.
Under the terms of the agreement, the Purchaser has agreed to purchase common stock at a per-share price of One Dollar ($1) per share, for a total purchase price of up to One Million Dollars ($1,000,000). In addition to the Shares, the Purchaser was issued a warrant to purchase shares of common stock of the Company at an exercise price of $2.50 per share. The number of shares underlying the Warrant will be equal to one share per $1.25 of the Purchase Price.
The venture company official declared, Our ability to formally engage with Braincure Biotech couldnt come at a better time. We are thrilled that we are able to commit to financially supporting the research and development of a novel method focused on evaluating an approach to Alzheimers Disease treatment that has been clinically recognized, but never before studied in a clinically significant way.
Braincure Biotech is working to establish a research foothold in an entirely new approach to the treatment of Alzheimers Disease. Never before has the need for effective treatments been greater, as incidence of this deadly and indiscriminate killer is expected to rise significantly in the next twenty five years, Suhon Horng, president and CEO of Braincure Biotech stated.
About Braincure Biotech